晚期非小细胞肺癌化疗免疫治疗中的肠道菌群:III期试验JCOG2007(NIPPON)的辅助生物标志物研究
本研究为III期JCOG2007(NIPPON)试验的辅助生物标志物分析,对295例入组患者中270例有基线粪便样本者行16S核糖体DNA测序。总体队列β多样性显示,总生存超过12或18个月亚群间微生物结构不同;Fusicatenibacter、Butyricicoccus和Blautia在总生存较长患者中富集。较低微生物α多样性和某些菌群与≥4级严重不良事件风险较高相关,而Fusicatenibacter和Butyricicoccus与严重不良事件风险较低相关。
要点
- 在270例晚期非小细胞肺癌患者中,总生存超过12或18个月者与未超过者微生物β多样性结构不同。
- Fusicatenibacter、Butyricicoccus和Blautia在总生存较长患者中富集。
- 较低α多样性和某些菌群与≥4级严重不良事件风险较高相关,Fusicatenibacter和Butyricicoccus与严重不良事件风险较低相关。
核心结论
- 肠道菌群可能作为晚期非小细胞肺癌化疗免疫治疗的生物标志物。
- 微生物多样性和特定细菌属的差异与预后和严重不良事件相关,并可能具有方案特异性效应。
研究设计与样本
- III期JCOG2007(NIPPON)试验的辅助生物标志物研究,比较帕博利珠单抗联合铂类双药化疗(PC)与纳武利尤单抗和伊匹木单抗联合铂类双药化疗(NIC)在无驱动基因改变的初治晚期非小细胞肺癌患者中的疗效。
- 295例入组患者中,270例有基线粪便样本者纳入肠道菌群组成分析,行16S核糖体DNA测序用于多样性和差异丰度分析。
主要发现
- 总体队列(n=270)β多样性分析显示,以总生存是否超过12或18个月定义的亚群间微生物结构不同。
- 线性判别分析效应量分析识别出亚群间差异的特定细菌属,Fusicatenibacter、Butyricicoccus和Blautia在总生存较长患者中富集。
- 较低微生物α多样性和某些分类群的存在与严重(≥4级)不良事件风险较高相关。
- 有益菌属包括Fusicatenibacter和Butyricicoccus与严重不良事件风险较低相关。
- 方案特异性分析显示,Fusicatenibacter和Butyricicoccus丰度较高与NIC组较CP组总生存更好相关(总生存风险比分别为0.56和0.52);Prevotellaceae NK3B31丰度较高与NIC组死亡风险较高相关(总生存风险比=2.33)。
临床怎么用
- 作者认为这些发现支持将肠道菌群分析整合入临床实践以优化一线治疗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immunotherapy has transformed the treatment for NSCLC. Nevertheless, reliable biomarkers for treatment selection remain scarce. Gut microbiota has emerged as a potential biomarker, but its role in chemoimmunotherapy for NSCLC is unclear. METHODS: The phase III trial (JCOG2007, NIPPON) compared pembrolizumab plus platinum doublet chemotherapy (PC) with nivolumab and ipilimumab plus platinum doublet chemotherapy (NIC) in treatment-naive patients with advanced NSCLC without driver gene alterations. As an ancillary biomarker study, 270 patients with baseline fecal samples were analyzed for gut microbiota composition from 295 patients enrolled. 16S ribosomal DNA sequencing was performed for the diversity and differential abundance analysis. RESULTS: The beta diversity analysis of the overall cohort (n = 270) revealed distinct microbial structures between the subpopulations defined by whether overall survival (OS) exceeds 12 or 18 months. Subsequent linear discriminant analysis effect size analysis identified specific bacterial genera that differed between the subpopulations, with Fusicatenibacter, Butyricicoccus, and Blautia being enriched in patients with longer OS. Regarding adverse events (AEs), lower microbial alpha diversity and the presence of certain taxa were linked to a higher risk of serious (≥grade 4) AEs. In addition, favorable genera, including Fusicatenibacter and Butyricicoccus, were associated with a lower risk of serious AEs. Last, regimen-specific analysis demonstrated that higher abundance of Fusicatenibacter and Butyricicoccus was linked to better OS in the NIC arm compared with that in the CP arm (hazard ratio for OS = 0.56 and 0.52, respectively). Conversely, the higher abundance of Prevotellaceae NK3B31 was associated with higher mortality risk in the NIC arm (hazard ratio for OS = 2.33). CONCLUSIONS: Gut microbiota may serve as a biomarker for chemoimmunotherapy in advanced NSCLC. Differences in microbial diversity and specific bacterial genera were associated with prognosis and serious AEs, with potential regimen-specific effects. These findings support integrating gut microbiota profiling into clinical practice to optimize first-line treatment strategies.
引用
- Hakozaki T, Tanaka K, Shiraishi Y, et al. Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON). J Thorac Oncol. 2025. PMID: 40058642. doi:10.1016/j.jtho.2025.02.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。